Conference Call with IOL Chemicals and Pharmaceuticals Management and Analysts on Q2FY25 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company IOL Chemicals and Pharmaceuticals announced H1FY25 & Q2FY25 results Q2FY25 Financial Highlights: Total Income: Rs 532.18 crore compared to Rs 552.41 crore during Q2FY24, change -3.66% YoY. EBITDA: Rs 47.99 crore compared to Rs 71.21 during Q2FY24, change -32.61% YoY. EBITDA Margin: 9.02% for Q2FY25. PAT: Rs 19.15 crore compared to Rs 37.79 crore during Q2FY24, change -49.33 YoY. PAT Margin: 3.60% for Q2FY25. H1FY25 Financial Highlights: Total Income: Rs 1041.94 crore compared to Rs 1122.65 crore during H1FY24, change -7.19% YoY. EBITDA: Rs 106.17 crore compared to Rs 151.13 during H1FY24, change -29.75% YoY. EBITDA Margin: 10.19% for H1FY25. PAT: Rs 48.83 crore compared to Rs 84.00 crore during H1FY24, change -41.87%YoY. PAT Margin: 4.69% for H1FY25. Vikas Gupta, Joint Managing Director, said: "We are pleased to report sustainable revenue growth in Q2FY25, reflecting the resilience of our core business. However, we faced some margin pressure during the quarter, driven by challenges in selling price. To address this, we are taking proactive measures to optimize marketing strategies, cost structure and enhance operational efficiencies, with the goal of improving profitability in the coming periods. Despite these challenges, we remain confident in the long-term growth potential of the business." Result PDF